Turn Therapeutics Reports Strong Phase 2 GX-03 Interim Data in Atopic Dermatitis

Turn Therapeutics announced interim analysis results from its Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis, showing 92.6% of treated subjects achieved 50% eczema severity reduction within 4 weeks with no serious adverse events. The positive efficacy and safety findings led the company to optimize the trial's second stage, potentially strengthening the drug candidate's regulatory pathway.